# Human FGFR2 / CD332 Protein (aa 400-821, His & GST Tag)

Catalog Number: 10824-H20B1



## **General Information**

### Gene Name Synonym:

BBDS; BEK; BFR-1; CD332; CEK3; CFD1; ECT1; JWS; K-SAM; KGFR; TK14; TK25

#### **Protein Construction:**

A DNA sequence encoding the human FGFR2 (NP\_000132.3) cytoplasmic domain (Met 400-Thr 821) was fused with the N-terminal polyhistidine-tagged GST tag at the N-terminus.

Source: Human

Expression Host: Baculovirus-Insect Cells

**QC** Testing

Purity: > 90 % as determined by SDS-PAGE

## **Bio Activity:**

1. The specific activity was determined to be 28 nmol/min/mg using Poly(Glu:Tyr) 4:1 as substrate. 2. Measured by its binding ability in a functional ELISA. Immobilized recombinant human FGFR2 (aa 400-821) (Cat:10824-H20B1) at 10  $\mu$ g/ml (100  $\mu$ l/well) can bind biotinylated human FGF acidic (Cat:10013-HNAE) with a linear range of 15.6-250 ng/ml. 3. Measured by its binding ability in a functional ELISA. Immobilized recombinant recombinant human FGFR2 (aa 400-821) (Cat:10824-H20B1) at 10  $\mu$ g/ml (100  $\mu$ l/well) can bind biotinylated human FGF basic (Cat:10014-HNAE) with a linear range of 0.16-1.25  $\mu$ g/ml.

#### **Endotoxin:**

< 1.0 EU per µg of the protein as determined by the LAL method

Predicted N terminal: Gln 26

#### **Molecular Mass:**

The recombinant human FGFR2 (aa 400-821) /GST chimera consists of 659 amino acids and predictes a molecular mass of 75.7 kDa. It migrates as an approximately 68 KDa band in SDS-PAGE under reducing conditions.

#### Formulation:

Supplied as sterile 20mM Tris, 500mM NaCl, pH 7.4, 10% gly

Normally 5 % - 8 % trehalose, mannitol and 0.01% Tween80 are added as protectants before lyophilization. Specific concentrations are included in the hardcopy of COA. Please contact us for any concerns or special requirements.

# **Usage Guide**

#### Stability & Storage:

Samples are stable for twelve months from date of receipt at -20  $^{\circ}$ C to -80  $^{\circ}$ C.


Store it under sterile conditions at  $-20^{\circ}$ C to  $-80^{\circ}$ C upon receiving. Recommend to aliquot the protein into smaller quantities for optimal storage.

Avoid repeated freeze-thaw cycles.

## Reconstitution:

Detailed reconstitution instructions are sent along with the products.

#### SDS-PAGE:



# **Protein Description**

FGFR2, also known as CD332, belongs to the fibroblast growth factor receptor subfamily where amino acid sequence is highly conserved between members and throughout evolution. FGFR2 acts as cell-surface receptor for fibroblast growth factors and plays an essential role in the regulation of cell proliferation, differentiation, migration and apoptosis, and in the regulation of embryonic development. It is required for normal embryonic patterning, trophoblast function, limb bud development, lung morphogenesis, osteogenesis and skin development. FGFR2 plays an essential role in the regulation of osteoblast differentiation, proliferation and apoptosis, and is required for normal skeleton development. It also promotes cell proliferation in keratinocytes and imature osteoblasts, but promotes apoptosis in differentiated osteoblasts. FGFR2 signaling is down-regulated by ubiquitination, internalization and degradation. Mutations that lead to constitutive kinase activation or impair normal CD332 maturation, internalization and degradation lead to aberrant signaling. Over-expressed FGFR2 promotes activation of STAT1. Defects in CD3322 are the cause of Crouzon syndrome, Jackson-Weiss syndrome, Apert syndrome, Pfeiffer syndrome, Beare-Stevenson cutis gyrata syndrome, familial scaphocephaly syndrome, lacrimo-auriculodento-digital syndrome and Antley-Bixler syndrome without genital anomalies or disordered steroidogenesis.

## References

1.Marie PJ, et al. (2003) Regulation of human cranial osteoblast phenotype by FGF-2, FGFR-2 and BMP-2 signaling. Histol. 17(3):877-85. 2.Park WJ, et al. (1996) Novel FGFR2 mutations in Crouzon and Jackson-Weiss syndromes show allelic heterogeneity and phenotypic variability. Hum Mol Genet. 4(7):1229-33. 3.Orr-Urtreger A, et al. (1993) Developmental localization of the splicing alternatives of fibroblast growth factor receptor-2 (FGFR2). Dev Biol. 158(2):475-86.